Product information and disease descriptionProduct descriptionProduct information
Product comparison
17 evidence topics · 17 sources
Palazestrant: class, dosing, and OPERA-01 population
“Palazestrant is a next-generation, orally bioavailable complete estrogen receptor antagonist (CERAN) and SERD with potent activity targeting the ER” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Palazestrant promotes ER degradation at levels similar to that of fulvestrant and greater than that of elacestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part 2, participants are randomized at a 1:1 ratio to receive once‑daily oral palazestrant (90 mg QD) or the investigator’s choice of SOC ET.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OPERA-01 (NCT06016738) is a phase III study designed to evaluate the safety and efficacy of palazestrant monotherapy compared to SOC ET in patients with ER+, HER2– locally advanced or metastatic breast cancer, regardless of ESR1 mutation status, whose disease advanced following treatment with at least one ET in combination with a CDK4/6i.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“trials investigating the efficacy of the PROteolysis Targeting Chimera ER degrader (PROTAC), vepdegestrant, and the SERD, imlunestrant, showed progression-free survival (PFS) benefits specific to patients harboring ESR1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Palazestrant: phase 1/2 formulation, efficacy, and comparison with other estrogen receptor-targeting agents
“All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 120 mg/day, the median progression-free survival was 4.8 months (95% CI, 3.5–7.1) overall and 5.6 months (95% CI, 4.8–NE) among patients with cancers with ESR1 mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, unlike with other SERDs that have reported rates of up to 45% for bradycardia and 56% for photopsia, the incidence of bradycardia and photopsia was lower with palazestrant (9% and 5%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CERAN/SERD mechanism of action of palazestrant is shared by fulvestrant, camizestrant and imlunestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Elacestrant, which is a selective ER modulator (SERM) and SERD, does not completely shut down ER signaling due to being an partial agonist and was also more active in cancers harboring ESR1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“although a direct comparison has not been performed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Palazestrant: competing estrogen receptor-targeting products named by the sponsor
Elacestrant (Orserdu): indication, regimen, EMERALD efficacy, and warnings
Elacestrant: EMERALD progression-free survival in all patients and in patients with ESR1 mutation
“PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elacestrant (Orserdu): wholesale acquisition cost at launch
| Strength | NDC | Pack size | WAC (as of date of commercial availability) | Date of commercial availability |
|---|---|---|---|---|
| 86 mg | “72187010103” | “30 tablets” | “$7,123.00” | “2/3/2023” |
| 345 mg | “72187010203” | “30 tablets” | “$21,369.00” | “2/3/2023” |
Imlunestrant (Inluriyo): indications, regimen, EMBER-3 efficacy, and warnings
Imlunestrant (Inluriyo): wholesale acquisition cost
| Strength and dosage form | NDC | Pack size | Wholesale acquisition cost |
|---|---|---|---|
| 200 mg tablet | “0002-1717-28” | “28” | “$11,250.00” |
| 200 mg tablet | “0002-1717-56” | “56” | “$22,500.00” |
Vepdegestrant (Veppanu): indication, regimen, VERITAC-2 efficacy, and warnings
Camizestrant (Etcamah): indication, regimen, SERENA-6 efficacy, and warnings
Fulvestrant (Faslodex): indications, regimen, CONFIRM efficacy, and warnings
Capivasertib (Truqap): indication, regimen, CAPItello-291 efficacy, and warnings
Capivasertib: CAPItello-291 progression-free survival in the overall and AKT pathway-altered populations
“In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AKT pathway–altered population, the median progression-free survival was 7.3 months in the capivasertib–fulvestrant group, as compared with 3.1 months in the placebo–fulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capivasertib (Truqap): wholesale acquisition cost of blister packs
| Product | NDC | Order quantity | WAC price |
|---|---|---|---|
| 160 mg tablets, 4 x 16 blister pack | “00310-9500-02” | “1 Blister Package (4x16)” | “$22,922.00” |
| 200 mg tablets, 4 x 16 blister pack | “00310-9501-02” | “1 Blister Package (4x16)” | “$22,922.00” |
Gedatolisib (Revtorpyk): indication, regimen, VIKTORIA-1 efficacy, and warnings
Gedatolisib: VIKTORIA-1 progression-free survival hazard ratios and discontinuation
“The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote